Sanghoon Cha's large shareholding report: AprilBio stake expands to 41.64% via third-party allotment and stock purchase agreement closing
The reporting person Sanghoon Cha and special relations increased their stake in AprilBio from 19.39% to 41.64% through the closing of an over-the-counter stock purchase agreement and a third-party allotment capital increase.
Total outstanding shares increased by 32.9% from 23,413,826 to 31,117,877, causing dilution for existing shareholders.
Shareholder agreements and joint investment agreements were signed among major shareholders, granting TKG Huchems preemptive rights and a call option, and IMM entities put options and tag-along rights.
IMM Scale-up Bio No.1 and IMM Healthcare No.8 pledged some of their shares as collateral, borrowing approximately KRW 40 billion and KRW 48 billion from Shinhan Investment Corp. and TKG Taekwang, respectively.
[AI Summary]The significant capital increase and debt-financed control reinforcement pose high dilution risk for existing shareholders, but the participation of credible financial investors provides short-term funding stability. Investors should monitor potential future equity changes from option exercises.